The biology and treatment of leiomyosarcomas.
Date
2023-04-01ICR Author
Author
Kerrison, WGJ
Thway, K
Jones, RL
Huang, PH
Type
Journal Article
Metadata
Show full item recordAbstract
Leiomyosarcoma (LMS) is a soft tissue sarcoma of smooth muscle origin that can arise in multiple anatomical sites and is broadly classified as extra-uterine LMS or uterine LMS. There is substantial interpatient heterogeneity within this histological subtype, and despite multi-modal therapy, clinical management remains challenging with poor patient prognosis and few new therapies available. Here we discuss the current treatment landscape of LMS in both the localised and advanced disease setting. We further describe the latest advances in our evolving understanding of the genetics and biology of this group of heterogeneous diseases and summarise the key studies delineating the mechanisms of acquired and intrinsic chemotherapy resistance in this histological subtype. We conclude by providing a perspective on how novel targeted agents such as PARP inhibitors may usher in a new paradigm of biomarker-driven therapies that will ultimately impact the outcomes of patients with LMS.
Collections
Subject
Doxorubicin
Genomics
Leiomyosarcoma
PARP inhibitors
Soft tissue sarcomas
Female
Humans
Leiomyosarcoma
Sarcoma
Antineoplastic Agents
Uterine Neoplasms
Biology
Research team
Mol and Systems Oncology
Language
eng
Date accepted
2023-03-04
License start date
2023-04-01
Citation
Critical Reviews in Oncology Hematology, 2023, 184 pp. 103955 -
Publisher
ELSEVIER SCIENCE INC